21,853 Shares in Tyra Biosciences, Inc. $TYRA Bought by PSP Research LLC

PSP Research LLC bought a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 21,853 shares of the company’s stock, valued at approximately $575,000. Tyra Biosciences accounts for about 0.5% of PSP Research LLC’s holdings, making the stock its 4th largest holding.

Several other hedge funds also recently bought and sold shares of the company. Commodore Capital LP boosted its holdings in Tyra Biosciences by 8.9% in the 3rd quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock worth $47,216,000 after buying an additional 275,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Tyra Biosciences by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company’s stock valued at $21,267,000 after purchasing an additional 118,492 shares during the last quarter. Balyasny Asset Management L.P. boosted its holdings in shares of Tyra Biosciences by 45.1% during the 3rd quarter. Balyasny Asset Management L.P. now owns 846,585 shares of the company’s stock valued at $11,844,000 after purchasing an additional 263,199 shares during the last quarter. Caligan Partners LP boosted its holdings in shares of Tyra Biosciences by 266.8% during the 3rd quarter. Caligan Partners LP now owns 696,825 shares of the company’s stock valued at $9,749,000 after purchasing an additional 506,875 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in shares of Tyra Biosciences by 40.6% during the 3rd quarter. Marshall Wace LLP now owns 602,015 shares of the company’s stock valued at $8,422,000 after purchasing an additional 173,907 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Trading Down 5.3%

Shares of NASDAQ TYRA opened at $33.78 on Wednesday. The firm’s 50-day moving average price is $36.17 and its 200-day moving average price is $29.36. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -15.50 and a beta of 0.79. Tyra Biosciences, Inc. has a 12-month low of $8.75 and a 12-month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.04). On average, equities analysts predict that Tyra Biosciences, Inc. will post -2.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TYRA has been the subject of several research reports. Wall Street Zen downgraded shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, January 24th. William Blair initiated coverage on shares of Tyra Biosciences in a report on Tuesday, February 10th. They set an “outperform” rating for the company. Wolfe Research initiated coverage on shares of Tyra Biosciences in a report on Tuesday. They set a “peer perform” rating for the company. Jefferies Financial Group increased their price objective on shares of Tyra Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a report on Tuesday, February 3rd. Finally, Guggenheim initiated coverage on shares of Tyra Biosciences in a report on Tuesday, April 14th. They set a “buy” rating and a $54.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.50.

Insiders Place Their Bets

In related news, Director Gilla Kaplan sold 14,295 shares of the stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the sale, the director directly owned 28,231 shares of the company’s stock, valued at $1,043,700.07. This represents a 33.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.50% of the stock is owned by company insiders.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.